Diseases, Conditions, Syndromes

Possible new drug for children with progeria

(Medical Xpress) -- A new study published in the journal Science Translational Medicine shows that rapamycin and its derivative everolimus, which is currently used to treat cancer and transplant rejections, may work to reverse ...

Medical research

A new pathway for an anti-aging drug

In 1972, Easter Island, called Rapa Nui, famous for its moai statues, offered a new wonder: the discovery of the drug rapamycin.

Medical research

Rapamycin may slow skin aging, study reports

The search for youthfulness typically turns to lotions, supplements, serums and diets, but there may soon be a new option joining the fray. Rapamycin, a FDA-approved drug normally used to prevent organ rejection after transplant ...

Diabetes

Experimental combo treatment worsens type 1 diabetes

(HealthDay)—A treatment regimen that is effective in preventing diabetes in a mouse model of the disease leads to worsening disease in patients with type 1 diabetes, according to a study published online June 20 in Diabetes.

page 1 from 5

Sirolimus

Sirolimus (INN/USAN), also known as rapamycin, is an immunosuppressant drug used to prevent rejection in organ transplantation; it is especially useful in kidney transplants. A macrolide, sirolimus was first discovered as a product of the bacterium Streptomyces hygroscopicus in a soil sample from Easter Island — an island also known as "Rapa Nui", hence the name. It is marketed under the trade name Rapamune by Wyeth.

Sirolimus was originally developed as an antifungal agent. However, this was abandoned when it was discovered that it had potent immunosuppressive and antiproliferative properties.

This text uses material from Wikipedia, licensed under CC BY-SA